N'-[N'-[4-fluoro-3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-[N'-[4-fluoro-3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide
• 化学式: C₁₄H₁₇F₄N₅
• 分子量: 331.31
• InChiKey: SOARXXJOEYYCCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same
  申请人：Kim Sung Wuk

  公开号：US20140179660A1

  公开（公告）日：2014-06-26

  An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

  提供了一种Formula 1的N1-环氨基-N5-取代苯基双胍衍生物或其药用盐，以及制备该化合物的方法，以及包含该双胍衍生物或其药用盐作为活性成分的药物组合物。这些双胍衍生物具有抑制癌细胞增殖的作用，并且还表现出抗癌活性，包括抑制癌症转移和癌症复发，因为它们能够有效激活与能量代谢控制相关的AMPK，即使与传统药物相比，以小剂量给药也具有显著效果。此外，这些双胍衍生物通过激活AMPK而高效降低血糖和血脂浓度，因此它们可能有效用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征和代谢综合征。
• N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Immunomet Therapeutics Inc.

  公开号：EP2742019B1

  公开（公告）日：2021-03-03
• US9540325B2
  申请人：——

  公开号：US9540325B2

  公开（公告）日：2017-01-10